SELE and chronic myelogenous leukemia, BCR-ABL1 positive: Blocking cell adherence using the E-selectin inhibitor GMI-1271 allowed CML-initiating cells to enter the cell cycle and thus achieve longer survival188 (Fig. 5.8).